Scholar Rock (SRRK) Projected to Post Earnings on Thursday

Scholar Rock (NASDAQ:SRRK - Get Free Report) is anticipated to release its earnings data before the market opens on Thursday, February 27th. Analysts expect Scholar Rock to post earnings of ($0.60) per share for the quarter. Individual interested in listening to the company's earnings conference call can do so using this link.

Scholar Rock Stock Performance

Shares of NASDAQ:SRRK traded down $1.45 on Friday, hitting $37.70. The company had a trading volume of 717,240 shares, compared to its average volume of 757,555. Scholar Rock has a 1-year low of $6.76 and a 1-year high of $46.98. The stock has a market cap of $3.53 billion, a price-to-earnings ratio of -16.04 and a beta of 0.50. The stock has a 50 day moving average price of $41.81 and a 200 day moving average price of $28.37. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Truist Financial upped their price target on shares of Scholar Rock from $36.00 to $45.00 and gave the company a "buy" rating in a research note on Monday, November 25th. Wedbush reaffirmed an "outperform" rating and issued a $47.00 target price on shares of Scholar Rock in a research report on Wednesday, January 29th. Finally, HC Wainwright upped their price objective on Scholar Rock from $40.00 to $50.00 and gave the company a "buy" rating in a report on Tuesday, November 26th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $40.43.

Insider Buying and Selling

In other news, CFO Edward H. Myles sold 12,539 shares of the stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $44.20, for a total transaction of $554,223.80. Following the sale, the chief financial officer now directly owns 148,549 shares of the company's stock, valued at approximately $6,565,865.80. This represents a 7.78 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Mo Qatanani sold 68,510 shares of the stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $37.40, for a total value of $2,562,274.00. Following the sale, the insider now directly owns 111,084 shares in the company, valued at approximately $4,154,541.60. This trade represents a 38.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 559,407 shares of company stock valued at $21,686,786 over the last 90 days. 19.20% of the stock is owned by corporate insiders.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.